Cargando…

Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease

Levodopa (L-DOPA) is the most effective drug for Parkinson's disease (PD). However, the response to L-DOPA remains individually variable, which hampers the practical value of L-DOPA in the clinic. Genetic factors play a role in L-DOPA efficacy. This study explored the associations between polym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lanting, Lin, Huixia, Hua, Ping, Yan, Lei, Dong, Hui, Li, Tan, Liu, Weiguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673431/ https://www.ncbi.nlm.nih.gov/pubmed/33250838 http://dx.doi.org/10.3389/fneur.2020.520934

Ejemplares similares

Case Report: Clinical Outcome From Pallidal Stimulation in a Patient With Levodopa-Resistant Dopa-Responsive Dystonia
por: Wang, Xue, et al.
Publicado: (2022)

Case report: Levodopa-responsive parkinsonism with akinetic mutism after ventriculo-peritoneal shunt
por: Zhang, Ying, et al.
Publicado: (2023)

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
por: Palacios, Natalia, et al.
Publicado: (2021)

Comparison of Three Motor Subtype Classifications in de novo Parkinson's Disease Patients
por: Ren, Jingru, et al.
Publicado: (2020)

Improvement of the Rett Syndrome Phenotype in a Mecp2 Mouse Model Upon Treatment with Levodopa and a Dopa-Decarboxylase Inhibitor
por: Szczesna, Karolina, et al.
Publicado: (2014)

Advances in Neurology, Volume 2. Treatment of Parkinsonism—The Role of Dopa Decarboxylase Inhibitors
por: Pincus, Jonathan H.
Publicado: (1974)

Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes
por: Li, Xin-yao, et al.
Publicado: (2021)

Gene polymorphisms and motor levodopa‐induced complications in Parkinson's disease
por: Michałowska, Małgorzata, et al.
Publicado: (2020)

Effects of Levodopa on Impairments to High-Level Vision in Parkinson's Disease
por: Anderson, Stephen, et al.
Publicado: (2020)

Electroanalytical Overview: The Determination of Levodopa (L-DOPA)
por: Crapnell, Robert D., et al.
Publicado: (2023)

Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
por: van Kessel, Sebastiaan P., et al.
Publicado: (2019)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Wang, Libo, et al.
Publicado: (2018)

Differences in Levodopa Response for Progressive and Non-Progressive Micrographia in Parkinson's Disease
por: Zham, Poonam, et al.
Publicado: (2021)

Novel polymorphisms of dopa decarboxylase gene and their association with lamb quality traits in Indonesian sheep
por: Harahap, Ratna Sholatia, et al.
Publicado: (2023)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation
por: Yi, Zhan-Miao, et al.
Publicado: (2018)

Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia
por: Sgroi, Stefania, et al.
Publicado: (2018)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease
por: Muthuraman, Muthuraman, et al.
Publicado: (2018)

Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
por: Diaconu, Ştefania, et al.
Publicado: (2023)

Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease
por: Nutt, John G., et al.
Publicado: (2020)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Evaluation of the Direct Effect of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus on Levodopa-Induced On-Dyskinesia in Parkinson's Disease
por: Li, Jiping, et al.
Publicado: (2021)

Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients With Parkinson’s Disease
por: Shen, Yang, et al.
Publicado: (2020)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Slurring of Speech and Lip Paresthesia: Symptoms of Levodopa End of Dose Wearing Off in Parkinson's Disease
por: Nasir, Usama, et al.
Publicado: (2018)

Interaction of Human Dopa Decarboxylase with L-Dopa: Spectroscopic and Kinetic Studies as a Function of pH
por: Montioli, Riccardo, et al.
Publicado: (2013)

Emerging Role of l-Dopa Decarboxylase in Flaviviridae Virus Infections
por: Frakolaki, Efseveia, et al.
Publicado: (2019)

Case report: Bilateral double beta peak activity is influenced by stimulation, levodopa concentrations, and motor tasks, in a Parkinson’s disease patient on chronic deep brain stimulation
por: Giannini, Giulia, et al.
Publicado: (2023)

Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism
por: Ogawa, Masatoshi, et al.
Publicado: (2019)

Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design
por: Brodell, David W, et al.
Publicado: (2012)

Anxiety and Levodopa Equivalent Daily Dose Are Potential Predictors of Sleep Quality in Patients With Parkinson Disease in Taiwan
por: Chang, Chun-Wei, et al.
Publicado: (2019)

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
por: Aljuaid, Maram, et al.
Publicado: (2019)

Overexpression of Tyrosine hydroxylase and Dopa decarboxylase associated with pupal melanization in Spodoptera exigua
por: Liu, Sisi, et al.
Publicado: (2015)

Four-Year Longitudinal Study of Motor and Non-motor Symptoms in LRRK2-Related Parkinson's Disease
por: Deng, Xiao, et al.
Publicado: (2020)

The Role of Single Nucleotide Polymorphisms of Monoamine Oxidase B, Dopamine D2 Receptor, and DOPA Decarboxylase Receptors Among Patients Treated for Parkinson’s Disease
por: Zapała, Barbara, et al.
Publicado: (2022)

Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia
por: Jeong, Eun Hye, et al.
Publicado: (2018)

Transcranial Magnetic Stimulation Alleviates Levodopa-Induced Dyskinesia in Parkinson's Disease and the Related Mechanisms: A Mini-Review
por: Wu, Yi, et al.
Publicado: (2021)

Neuropathological features of levodopa-responsive parkinsonism in multiple system atrophy: an autopsy case report and comparative neuropathological study
por: Tamura, Mitsuyoshi, et al.
Publicado: (2023)

Identification by Virtual Screening and In Vitro Testing of Human DOPA Decarboxylase Inhibitors
por: Daidone, Frederick, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hvvlbks33fasbcm09o6104qglj